Iaso Therapeutics
PrivateLast Round
Seed
Jan 25, 2023
Total Funding Raised
$3.17M
Company Overview
Iaso Therapeutics is a biotechnology company that develops next-generation vaccines using a proprietary mutant bacteriophage Qβ (mQβ) platform technology to treat cancer and infectious diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Iaso Therapeutics Comparables
Compare Iaso Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| VLP the Vaccines Company | 83% | |
| VLP Therapeutics | 81% | |
| VLP Biotech, Inc. | 81% |
Iaso Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Jan 25, 2023 | ||||
| Grant | Mar 1, 2022 | ||||
| Grant | Jul 15, 2021 | ||||
| Pre Seed | May 31, 2021 | ||||
| Grant | Apr 26, 2021 | ||||
Grant | Sep 18, 2020 |
Iaso Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| National Institute of Allergy and Infectious Diseases | Grant |
| Apjohn Group | Seed |
| Michigan Rise | Seed |
| Michigan State University Student Venture Capital Fund | Grant, Pre Seed |
| Michigan Rise and Red Cedar Ventures | Grant |
| Red Cedar Ventures Pre-Seed Fund | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 25, 2026
Monthly visitors increased 56% MoM.
- Mar 31, 2026
Will present at the 2026 World Vaccine Congress on March 31, 2026.
Iaso Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Iaso Therapeutics's valuation, stock price, and market status.
Is Iaso Therapeutics a public or private company?
Iaso Therapeutics is a private company.
What is the current stock price of Iaso Therapeutics?
Iaso Therapeutics is a private company, so its shares have no public market price. Caplight tracks Iaso Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Iaso Therapeutics worth (valuation)?
Valuation information for Iaso Therapeutics is not publicly available.
Can I buy Iaso Therapeutics stock?
Iaso Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Iaso Therapeutics's last funding round?
Iaso Therapeutics's most recent funding round was Seed on January 25, 2023.
Who are the main investors in Iaso Therapeutics?
Key investors in Iaso Therapeutics include National Cancer Institute, National Institute of Allergy and Infectious Diseases, Apjohn Group, Michigan Rise, Michigan State University Student Venture Capital Fund.
Will Iaso Therapeutics IPO soon?
No public IPO plans have been announced for Iaso Therapeutics.
How can I track Iaso Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Iaso Therapeutics's shares on secondary markets.